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Epigenetic Modiﬁcations in the Development of
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Introduction: Epigenetics is playing a decisive role in the
regulation of gene expression. Furthermore, pathological
epigenetic changes have already been associated with
various diseases, especially cancer. However, few data are
so far available about epigenetic modiﬁcations in athero-
sclerotic lesions. Therefore, we investigated histone
methylation and acetylation in different stages of athero-
sclerosis in patients with carotid artery stenosis.
Methods: Carotid plaques (n ¼ 120) from our biobank were
classiﬁed histologically according to AHA and divided as
early (type IeIII, n ¼ 60) or advanced (type VeVII, n ¼ 60)
stage of atherosclerosis. Twelve healthy vessels served as
controls. Expression of histone methyl and acetyl-
transferases were analysed by SYBRgreen-based real-time
RT-PCR. Immunohistochemistry and western blotting were
performed to quantify expression at protein level and to
associate histone methylation with the individual cells
within the atherosclerotic plaques.
Results: In atherosclerosis, methylation of H3K4 was unal-
tered. In contrast methylation of H3K9 and H3K27 were
signiﬁcantly decreased, compared to control arteries.
Expression of H3K4 was increased and H3K9 decreased in
smooth muscles, whereas H3K9 and H3K27 were reduced in
inﬂammatory cells in advanced versus early atherosclerosis.
MML2 and G9a signiﬁcantly increased in advanced versus
early atherosclerosis, and a signiﬁcant decrease in expres-
sion of G9a was observed between controls and early
stages. Increased histone acetylation was observed on H3K9
and H3K27 in SMCs in advanced atherosclerotic lesions
compared to healthy vessels, acetylation of H3 at position
K9 in SMCs and macrophages was associated with plaque
progression. Expression of acetyltransferase GCN5L and
MYST1 correlated with severity of atherosclerosis.
Conclusion: The extent of histone methylation and acetyla-
tion, as well the expression of corresponding transferases
were signiﬁcantly altered in atherosclerotic lesions and were
signiﬁcantly associated with the progression of atheroscle-
rosis, thus suggesting an important contribution of epige-
netic mechanisms to plaque progression and vulnerability.
Dysfunctional Endothelial Progenitor Cells may Contribute to
Vasculopathy in Systemic Sclerosis
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College London, UKIntroduction: Vascular complications associated with sys-
temic sclerosis (SSc) including pulmonary arterial hyper-
tension (PAH-SSc), result from endothelial damage and loss
of barrier function. The causes of endothelial dysfunction
are unclear, but endothelial integrity is likely to be signiﬁ-
cantly diminished in SSc. Endothelial progenitor cells (EPCs)
derived from peripheral blood mononuclear cells (PBMCs)
express endothelial and haematopoietic markers. It is
thought they home to sites of vascular injury and differ-
entiate into endothelial cells and restore the barrier. In SSc
patients circulating levels of EPCs are reduced. This study
aimed to: (i) Develop a robust method to isolate, grow and
characterise healthy control (HC) and SSc EPCs from PBMCs.
(ii) Compare the cellular functions of EPCs to mature
endothelial cells. (iii) Elucidate the functional role of EPCs in
SSc vasculopathy.
Methods: Peripheral blood was taken from HC (n ¼ 10) and
SSc donors (n ¼ 10). EPCs were cultured from PBMCs. EPCs
were characterised by ﬂow cytometry, then EPCs and hu-
man pulmonary artery endothelial cells (hPAECs) were
seeded into transwell inserts and grown to conﬂuence. Cells
were incubated with TNFa (10 ng/ml), and their capacity to
form biological barriers and support immune cell inﬂux was
assessed using FITC-albumin (0.5 mg/ml) and neutrophil
transmigration. We further assessed the responses of EPCs
to TNFa stimulation by ELISA to quantify pro-inﬂammatory
cytokine release.
Results: We demonstrate that EPCs, characterised by ﬂow
cytometry to be CD34+/CD31+/VEGFR2+/CD105+ and
CD133+, can form biological barriers with similar capabil-
ities as mature hPAECs in vitro. TNFa signiﬁcantly enhanced
permeability of EPCs (P < 0.05) and hPAECs (P < 0.05)
monolayers. Mixed cultures of 10% SSc-EPCs and 90%
mature PAECs signiﬁcantly enhanced endothelial perme-
ability compared to HC-EPC/PAECs mixed cultures. Consis-
tent with EPCs possessing similar cellular activities as
mature endothelial cells, TNFa stimulated neutrophil
transmigration in monolayers of EPCs (P < 0.05) and
hPAECs (P < 0.05) and enhanced the secretion of IL-8 in
both EPCs (P < 0.01) and hPAECs (P < 0.05).
Conclusion: We have demonstrated that endothelial pro-
genitors can maintain an endothelial barrier consistent with
that observed by mature hPAECs in vitro; established that
endothelial barriers consisting of both EPCs and mature
endothelial cells are dysfunctional in SSc; and ﬁnally, shown
that EPCs respond to TNFa in a similar manner to mature
PAECs, secreting pro-inﬂammatory cytokines such as IL-8
and supporting neutrophil transmigration. The biological
function and importance of EPCs from SSc patients in vas-
culopathy, restoration and maintenance of the endothelial
barrier function remains unclear.
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(CLI) eventually require amputation. In spite of clinically
successful revascularisation patients rarely return to their
pre-morbid status, and often report no improvement in
their functional outcomes, which may be due to an un-
derlying musculopathy. Non-haematopoietic EPO-de-
rivatives have been designed to retain only tissue-protective
functions of EPO. We hypothesised that ARA-290 (EPO-de-
rivative) may have tissue-protective potential that would
represent a novel therapeutic adjunct in patients with CLI.
Methods: The effect of EPO and ARA-290 in mediating
cytoprotection was assessed ﬁrstly in vitro using skeletal
myoblasts isolated from CLI and control donors, and a
model of simulated ischaemia. Characterisation of CLI
myoblasts was also performed, to assess their contractile,
migratory and proliferative ability. Subsequently, an in vivo
murine model of hindlimb ischaemia, which recapitulates
the muscular pathology observed in CLI patients, was used
to assess the potential of ARA-290 to improve functional,
histological and perfusion outcomes.
Results: Skeletal myoblasts were successfully isolated from
CLI patients for the ﬁrst time. CLI myoblasts and myotubes
exhibited increased proliferative capacity but reduced
migratory and contractile function and importantly a
reduced susceptibility to a second ischaemic-insult
compared with control myoblasts and myotubes. EPO and
ARA-290 treatment led to signiﬁcant improvements in
myoblasts and myotube function and survival via the JAK2/
STAT3, PI3k/Akt and NFkB signalling pathways. In vivo,
animals treated with EPO and ARA-290 demonstrated
improved functional, histological and perfusion outcomes
compared to vehicle-control treated animals.
Conclusion: These studies demonstrate the potential of EPO
and its derivatives to protect tissues and cells from
ischaemic-injury and encourages the development of novel
pharmacological therapies for use in patients with “no op-
tion” CLI or severe functional deﬁcit.
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Introduction: Immature plaque neovessels contribute to
atherosclerotic plaque instability and intraplaque hemor-
rhage by leaking erythrocytes and leukocytes in the plaque.
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2),
together with the angiopoietin (Ang)-Tie2 system, regulates
the maturation of growing neovessels. We have previously
shown that murine vein graft lesions exhibit massive plaqueneovascularization and that leaky vessels and intraplaque
hemorrhage contribute to lesion growth. We hypothesized
that blockade of VEGFR2 results in more mature plaque
microvessels and less intraplaque hemorrhage.
Methods: Donor caval veins were engrafted in carotid ar-
teries of recipient hypercholesterolemic ApoE3*Leiden mice
(n ¼ 14/group). Mice were treated at day 14, 17, 21 and 25
with VEGFR2 blocking antibodies (DC101) or control IgG
antibodies (10 mg/kg). At day 28 mice were sacriﬁced for
histological analysis of the vein grafts.
Results: Morphometric analysis revealed a striking 50%
decrease in vein graft segments that expressed intraplaque
haemorrhage in the form of leaky vessels in the DC101
treated group. This was accompanied by a signiﬁcant 25-
fold decrease in extravasated erythrocytes. Furthermore,
lesions that exhibit intraplaque hemorrhage showed a
strong increase in Ang-2, indicative for immature neo-
vessels. VEGFR2 blockade however, did not affect the neo-
vessel density in the lesions (control 52  19 neovessels/
section; DC101 63  25 neovessels/section). Interestingly,
the vein graft lesion area in the DC101 group was signiﬁ-
cantly reduced with 32% compared to the control group.
Moreover, plaque stability was clearly increased in DC101
treated mice, determined by a 25% reduction in macro-
phage content, a 50% increase in collagen content and a
120% increase in SMC content.
Conclusion: Blockade of VEGFR2 leads to reduced intra-
plaque hemorrhage, decreased vein graft lesion area and
increased plaque stability. This identiﬁes plaque neo-
vascularization as an attractive target for the treatment of
unstable atherosclerotic diseases.
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Introduction: TLR4-mediated mobilisation and activation of
pro-inﬂammatory Ly6Chi monocytes is crucial for effective
post-ischemic neovascularisation, i.e. arteriogenesis and
angiogenesis. Therefore, we aimed to investigate the role of
the TLR4-accessory molecule RP105 (CD180) in neo-
vascularisation. RP105 has been identiﬁed as a negative
regulator of TLR4 signalling in monocytes. Using immuno-
histochemical analyses, we found that RP105+monocytes are
present in the perivascular space of remodelling collateral
arterioles. As RP105 inhibits TLR4 signalling, we hypothesized
that RP105 deﬁciency would lead to an unrestrained TLR4-
mediated inﬂammatory response and hence to enhanced
neovascularisation and blood ﬂow recovery after ischemia.
Methods: RP105/ and wildtype mice were subjected to
hind limb ischemia and blood ﬂow recovery was followed
by Laser Doppler Perfusion Imaging during four weeks.
